Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Myo Maung Maung Swe and Htet Htet Aung from our MOCRU unit in Myanmar were awarded grants by the International Society for Infectious Diseases and Wellcome. Myo Maung will study antibiotics use and antimicrobial resistance public awareness in Myanmar; Htet Htet will conduct a study on Ethical challenges when offering pregnant women with Hepatitis B short course treatment to prevent transmission.

Dr Myo Maung Maung Swe and Htet Htet Aung

Dr Myo Maung Maung Swe (left), Clinical Researcher and DPhil student at MOCRU, was awarded in August an International Society for Infectious Diseases (ISID) research grant, a signature ISID program that funds infectious disease researchers from LMIC countries with the greatest burden of infectious disease. Myo Maung, a clinical researcher at MOCRU for 3 years, was awarded the ISID research grant to conduct the study Antibiotics use and antimicrobial resistance (AMR) public awareness survey in Myanmar. Myo plans to conduct the study, which aims to understand self-reported antibiotic use, public knowledge of antibiotics and the awareness of antibiotic resistance, in two regions of Myanmar, as yet to be determined. The team will collect data Dec 2018-Jan 2019 and hopes to publish results by April 2019.

That same month, MOCRU Clinical Research Assistant Htet Htet Aung (right) was awarded an Ethox Global Health Bioethics Network (GBHN) Bursary Award. GBHN is funded by a Wellcome Trust Strategic Award aiming to conduct ethics research and improve capacity building across the Wellcome Trust Major Overseas Programmes. Htet Htet, who has worked as a clinical research assistant in MOCRU for a year, will use the GBHN Bursary to conduct the study Ethical challenges related to offering pregnant women with chronic Hep B short course treatment with Tenofovir disoproxil fumarate to prevent vertical transmission in Myanmar. Htet Htet hopes to start the study mid-Oct, once she gets OxTREC and local Ethics Committee approval, and publish results in early June 2019. The study will be conducted at Central Women’s Hospital, Yangon.

Similar stories

AMR and scrub typhus among Chiangrai Unit's research priorities

Which infections are most common in the Chiangrai region? How should we treat them and how can we improve diagnostic? Which strategies are most effective in directing antibiotic treatment? Blog by Carlo Perrone, research physician based at the Chiang Rai Clinical Research Unit in Chiangrai, Thailand.

Researchers call for access to Ivermectin for young children

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

The COVID-19 vaccine: do we know enough to end the pandemic?

Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.

New study on the risk of Plasmodium vivax parasitaemia after Plasmodium falciparum malaria

A new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.